Sort   by:  
 Page size 
UnknownAssociation between hemoglobin/red blood cell distribution width ratio and acute kidney injury in sepsis and heart failure patients.

Introduction

The hemoglobin/red blood cell distribution width (Hb/RDW) ratio has emerged as a potential biomarker for acute kidney injury (AKI), particularly in patients with cardiovascular conditions. This study investigated the relationship between Hb/RDW ratio and AKI incidence in critica...
S-EPMC12948117 | biostudies-literature
UnknownConsistent improvement with eculizumab across muscle groups in myasthenia gravis.

Objective

To assess whether eculizumab, a terminal complement inhibitor, improves patient- and physician-reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti-ac...
S-EPMC7448154 | biostudies-literature
UnknownGlobal Roadkill Data: a dataset on terrestrial vertebrate mortality caused by collision with vehicles.
Roadkill is widely recognized as one of the primary negative effects of roads on many wildlife species and also has socioeconomic impacts when they result in accidents. A comprehensive dataset of roadkill locations is essential to evaluate the factors contributing to roadkill risk and to enhance our...
S-EPMC11958749 | biostudies-literature
UnknownAnimal models for COVID-19.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the introduction of a novel coronavirus into humans late in 2019 (first detected in Hubei province, China). As of 18 September 20...
S-EPMC8136862 | biostudies-literature
UnknownEculizumab improves fatigue in refractory generalized myasthenia gravis.

Purpose

To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue subscale, and to evaluate correlations betw...
S-EPMC6620379 | biostudies-literature
UnknownDevelopment of a Clinical Prediction Model for Anastomotic Leakage in Colorectal Surgery.

Importance

Anastomotic leakage is a severe complication after colorectal surgery that can significantly affect clinical outcomes and patient prognosis. Although multiple risk factors for anastomotic leakage have been identified, predicting the incidence of anastomotic leakage remains difficu...
S-EPMC12538359 | biostudies-literature
Unknown'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.

Background

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension.

Met...

S-EPMC7320935 | biostudies-literature
UnknownEarly Treatment with Pegylated Interferon Lambda for Covid-19.

Background

The efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19) is unclear.

Methods

We conducted a randomized, controlled, adaptive platform trial involving predominantly...
S-EPMC9933926 | biostudies-literature
UnknownEfficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.

Background

NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b-3 trials in the United Kingdom and South Africa, but its efficacy had not yet been tested in ...
S-EPMC8693692 | biostudies-literature
UnknownLong-term safety and efficacy of eculizumab in generalized myasthenia gravis.

Introduction

Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term saf...
S-EPMC6619057 | biostudies-literature
Sort   by:  
 Page size